Bharat Parenterals Ltd

Bharat Parenterals Ltd

Bharat Parenterals Ltd has scheduled an Extraordinary General Meeting (EGM) to be held on October 23, 2026, to consider a special resolution for the preferential allotment of equity shares.

Bharat Parenterals Ltd

Bharat Parenterals Ltd has announced the outcome of its board meeting, where it approved the preferential allotment of up to 9,12,759 equity shares at Rs. 1522.85 per share for an aggregate consideration of Rs. 138,99,95,043.15. The company will convene an EGM on October 23, 2026, to seek shareholder approval for the preferential issue.

Bharat Parenterals Ltd

Bharat Parenterals Ltd has announced the closure of its trading window from October 1, 2026, until 48 hours after the declaration of its unaudited financial results for the quarter and half year ended September 30, 2026.

Bharat Parenterals Ltd

Bharat Parenterals Ltd has scheduled a board meeting on September 29, 2026, to consider a preferential issue of shares and other business matters.

Bharat Parenterals Ltd

Bharat Parenterals Ltd has announced the voting results of its 33rd Annual General Meeting (AGM) held on September 19, 2026. All six resolutions were passed with majority votes, including the approval of audited financial statements, final dividend declaration, and re-appointment of directors.

Bharat Parenterals Ltd

Bharat Parenterals Ltd has announced the 33rd Annual General Meeting scheduled for September 19, 2026, through Video Conferencing / Other Audio-Visual Means. The company has also published a newspaper advertisement in Business Standard (English) and Vadodara Samachar (Gujarati) as per Regulation 30 and Regulation 47 of SEBI Listing Regulations.

Bharat Parenterals Ltd

Bharat Parenterals Ltd has dispatched a letter to shareholders whose email addresses are not registered with the company, providing a web-link to access the Annual Report for FY 2025-26 and the Notice convening the 33rd Annual General Meeting (AGM).

Bharat Parenterals Ltd

Bharat Parenterals Ltd has announced the record date for the payment of dividend for FY 2025-26 as September 12, 2026. Shareholders whose names appear in the books as beneficial owners as at the close of business hours on September 12, 2026, will be entitled to the dividend.

Bharat Parenterals Ltd

Bharat Parenterals Ltd has released its Annual Report for the Financial Year 2025-26, including the Notice of the 33rd Annual General Meeting scheduled for September 19, 2026.

Bharat Parenterals Ltd

Bharat Parenterals Ltd has announced the 33rd Annual General Meeting (AGM) of the company, scheduled to be held on September 19, 2026, through Video Conferencing (VC) or Other Audio-Visual Means (OAVM). The company has also provided the schedule for remote e-voting/e-voting during the AGM.

Bharat Parenterals Ltd

Bharat Parenterals Ltd has announced the publication of a pre-newspaper advertisement for its 33rd Annual General Meeting (AGM) to be held on September 19, 2026, through video conferencing.

Bharat Parenterals Ltd

Bharat Parenterals Ltd has been permitted to trade and admitted to dealings on the National Stock Exchange of India Limited, effective from August 17, 2026.

Bharat Parenterals Ltd

Bharat Parenterals Ltd has announced a newspaper notice informing shareholders about a special window for re-lodging transfer requests for physical shares that were lodged prior to April 1, 2019, and rejected or returned due to deficiencies in documents or process.

Bharat Parenterals Ltd

Bharat Parenterals Ltd's wholly owned subsidiary Varenyam Biolifesciences Private Ltd is upgrading its upcoming Savli manufacturing facility to offer biologics and biosimilar CDMO services for US, EU, and SRA RoW markets. The revised Phase 1 capital expenditure is ₹300 crore, up from ₹150 crore.

Bharat Parenterals Ltd

Bharat Parenterals Ltd has announced an analyst and investor meet under Regulation 30 of SEBI (LODR) on August 13, 2026, at Emkay Global Financial Services Ltd in Mumbai.

Bharat Parenterals Ltd

Bharat Parenterals Ltd published a newspaper advertisement for its unaudited financial results for the quarter ended June 30, 2026, in Business Standard and Vadodara Samachar Newspaper on August 7, 2026.

Bharat Parenterals Ltd

Bharat Parenterals Ltd has reported a 19% YoY decline in revenue to ₹93.7 Cr for Q1 FY27, primarily due to a one-time decline in standalone revenue. Gross margin improved by 1,000 bps to 50.6%, while EBITDA declined by 38% YoY to ₹8.5 Cr due to increased operating expenses. The company's subsidiaries, Innoxel and Varenyam Healthcare, have shown significant growth, contributing 46% of consolidated revenue before eliminations.

Bharat Parenterals Ltd

Bharat Parenterals Ltd has announced the re-appointment of Mr. Hemang Shah as Executive Director of the company, subject to shareholder approval at the upcoming AGM.

Bharat Parenterals Ltd

Bharat Parenterals Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with the board of directors approving and taking on record the results. The company has also fixed the date for its 33rd Annual General Meeting and approved the re-appointment of an executive director.

Bharat Parenterals Ltd

Bharat Parenterals Ltd has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, and has also approved the re-appointment of Mr. Hemang Shah as an executive director for a term of 5 years, subject to shareholder approval. The company has also fixed the date of its 33rd Annual General Meeting as September 19, 2026, through video conferencing.